SEC Form 4
Ironwood Pharmaceuticals, Inc. (IRWD) insider trading
In the 12 months to Oct 26, 2026, 3 IRWD insiders reported open-market sales of $21.4M across 4 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $21.4M
- 4 filings · 3 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 3 of 4
- $821.4K of $21.4M sold (4%)
Who traded IRWD, and when
- Sale
- Sale, pre-arranged (10b5-1)
IRWD daily close from Oct 27, 2025 to Oct 26, 2026, between $1.50 and $5.39, last $3.49. 4 sale and 0 purchase filings by 3 insiders, marked at their filing dates. Alexander J. Denner, Director: sold $20.5M across 1 filing, first filed Mar 17, 2026, last Mar 17, 2026. Ronald Silver, Principal Accounting Officer → PFO & PAO: sold $741.0K across 2 filings, first filed Jan 7, 2026, last Jul 9, 2026. Julie McHugh, Director: sold $80.5K across 1 filing, first filed Jun 17, 2026, last Jun 17, 2026.
Largest mark · tap a row for others
Alexander J. Denner · Director
Sale $20,530,448
6,730,800 shares at $3.05 avg
Filed Mar 17, 2026
Close on filing date $3.25
Alexander J. Denner · Director
Director
$20.5M soldRonald Silver · Principal Accounting Officer → PFO & PAO
Principal Accounting Officer → PFO & PAO
$741.0K soldJulie McHugh · Director
Director
$80.5K soldOpen-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Alexander J. Denner | Director | $20.5M | — | 1 | — | |
| Ronald Silver | Principal Accounting Officer → PFO & PAO | $741.0K | — | 2 | 100% of sales | |
| Julie McHugh | Director | $80.5K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Ronald Silver PFO & PAO | SalePre-arranged (10b5-1) | 127,890 | $4.52 | $578.1K | 313,680 | |
traded | Julie McHugh Director | SalePre-arranged (10b5-1) | 21,571 | $3.73 | $80.5K | 250,749 | |
traded | Alexander J. Denner Director | Sale | 6,730,800 | $3.05 | $20.5M | 9,188,635 | |
traded | Ronald Silver Principal Accounting Officer | SalePre-arranged (10b5-1) | 35,416 | $4.60 | $162.9K | 276,809 |
GET /stocks/filings/vX/form-4?tickers=IRWD&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"IRWD"
],
"issuer_cik": "0001446847",
"owner_cik": "0001873731",
"accession_number": "0001193125-26-299749",
"form_type": "4",
"filing_date": "2026-07-09",
"period_of_report": "2026-07-07",
"issuer_name": "IRONWOOD PHARMACEUTICALS INC",
"issuer_trading_symbol": "IRWD",
"owner_name": "Silver Ronald",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "PFO & PAO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-07-07",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 127890,
"transaction_price_per_share": 4.52,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 313680,
"transaction_value": 578062.7999999999,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."
},
{
"id": "F2",
"description": "The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.57, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."
}
]
},
{
"tickers": [
"IRWD"
],
"issuer_cik": "0001446847",
"owner_cik": "0001487179",
"accession_number": "0001193125-26-274275",
"form_type": "4",
"filing_date": "2026-06-17",
"period_of_report": "2026-06-16",
"issuer_name": "IRONWOOD PHARMACEUTICALS INC",
"issuer_trading_symbol": "IRWD",
"owner_name": "McHugh Julie",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-16",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 21571,
"transaction_price_per_share": 3.73,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 250749,
"transaction_value": 80459.83,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."
},
{
"id": "F3",
"description": "The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 32 records
- Tax withholding (sold to cover)13 records
- Grants and awards19 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Ironwood Pharmaceuticals, Inc.'s CEO sold stock?
No. Thomas A. MCCOURT (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is IRWD’s insider data?
These are IRWD Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track IRWD insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for IRWD every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.